[Skip to Content]
[Skip to Content Landing]
Evolving Issues in Oncology
February 15, 2019

Patients and Physicians in the Era of Modern Cancer Care

Author Affiliations
  • 1Stanford University School of Medicine, Stanford, California
JAMA. 2019;321(9):829-830. doi:10.1001/jama.2018.17334

Cancer care has undergone a revolution, driven by advances in the understanding of cancer biology and new therapeutics derived from that understanding. Many patients diagnosed as having cancer in the 1990s received relatively ineffective, toxic chemotherapeutics. Today, a patient encountering an oncologist might undergo a tumor biopsy with the goal of evaluating hundreds of oncogenic mutations. That patient then receives one of the many targeted therapeutics (eg, kinase inhibitors, monoclonal antibodies) or immuno-oncology agents in the ever-expanding therapeutic armamentarium, many developed within the past decade.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words